Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Lung Cancer Clinical Trial

Official title:

Carboplatin and Paclitaxel Plus ASA404 as First Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer (ES-SCLC): A Phase II Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01057342
• Other study ID #: SAKK 15/08
• Secondary ID: SWS-SAKK-15-08EU
• Status: Completed
• Phase: Phase 2
• First received: January 26, 2010
• Last updated: April 9, 2013
• Start date: January 2010
• Est. completion date: July 2012

Study information

• Verified date: April 2013
• Source: Swiss Group for Clinical Cancer Research
• Contact: n/a
• Is FDA regulated: No
• Health authority: Switzerland: Swissmedic
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Dimethylxanthenone acetic acid may stop the growth of small cell lung cancer by blocking blood flow to the tumor. Giving paclitaxel and carboplatin together with dimethylxanthenone acetic acid may kill more tumor cells.

PURPOSE: This phase II trial is studying the side effects of giving paclitaxel and carboplatin together with dimethylxanthenone acetic acid and to see how well they work in treating patients with extensive-stage small cell lung cancer.

Description:

OBJECTIVES:

Primary

• To assess the 24-week (6 months) progression-free survival of patients with extensive stage small cell lung cancer treated with paclitaxel, carboplatin, and dimethylxanthenone acetic acid.

Secondary

• To assess efficacy and safety of this regimen in these patients.

• To evaluate predictive molecular markers for gene expression analyses, serum proteomics, and pharmacogenomics. (exploratory)

OUTLINE: This is a multicenter study.

Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30 minutes, and dimethylxanthenone acetic acid IV over 20 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Blood and tissue samples may be collected periodically for predictive molecular markers for gene expression analysis, plasma proteomics, and pharmacogenomics.

After completion of study treatment, patients are followed every 6 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 17
• Est. completion date: July 2012
• Est. primary completion date: May 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

DISEASE CHARACTERISTICS:

• Histologically (preferred) or cytologically confirmed small-cell lung carcinoma (SCLC) by surgical biopsy, brushing, washing, OR core needle aspiration (sputum cytology alone not acceptable)

• Extensive stage or stage IV disease, including patients with malignant pleural or pericardial effusion

• No pleural effusion that causes = CTC grade 2 dyspnea

• Not suitable for potentially curative combined-modality treatment for this disease

• Measurable or non-measurable disease

• No CNS metastases

PATIENT CHARACTERISTICS:

• WHO performance status 0-2

• Hemoglobin = 10.0 g/dL

• Absolute neutrophils = 2.0 x 10^9/L (without the use of growth factors)

• Platelet count = 100 x 10^9/L

• Bilirubin = 1.5 x the upper limit of normal (ULN)

• ALT = 2.5 x ULN (= 5 x ULN if liver metastases)

• Alkaline phosphatase = 2.5 x ULN (= 5 x ULN if liver metastases)

• Creatinine clearance = 45 mL/min

• INR = 1.5

• Magnesium, potassium, and calcium (corrected for albumin) normal

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception during and for 12 months after completion of study therapy

• No recent hemoptysis associated with SCLC (> 1 teaspoon in a single episode within 4 weeks)

• No other malignancy within the past 5 years except for nonmelanoma skin cancer or cervical cancer in situ

• Must not have a history of any of the following conditions:

• Myocardial infarction within the past 12 months

• Uncontrolled hypertension (systolic BP > 160 mm Hg and/or diastolic BP > 90 mm Hg) or poor compliance with anti-hypertensive regimen

• Sustained ventricular tachycardia

• Ventricular fibrillation or Torsades de Pointes

• Long QT syndrome

• QTc of > 450 msec

• NYHA class III or IV congestive heart failure

• Unstable or poorly controlled angina pectoris, including Prinzmetal variant angina pectoris

• Right bundle branch block and left anterior hemiblock (bifascicular block)

• Bradycardia (defined as heart rate < 50 beats per minute)

• Cardiac arrhythmias (i.e., symptomatic, but may not require medications) CTCAE grade = 2

• No significant neurologic or psychiatric disorder that would compromise study participation

• No peripheral sensory neuropathy with functional impairment = CTC grade 2 (regardless of cause)

• No concurrent severe and/or uncontrolled medical disease, including any of the following:

• Uncontrolled diabetes

• Chronic renal disease

• Chronic liver disease

• Confirmed diagnosis of HIV infection

• Active uncontrolled infection

• No serious underlying medical condition, in the judgment of the investigator, that would impair the patient's ability to participate in the trial

• No known hypersensitivity to study drugs or to any other component of the study drugs (taxanes or other drugs formulated in Cremophor EL [polyoxyethylated castor oil])

PRIOR CONCURRENT THERAPY:

• Recovered from all prior therapy

• No prior systemic chemotherapy, immunotherapy, or biologic anti-cancer therapy

• More than 2 weeks since prior and no concurrent radiotherapy

• Localized palliative radiotherapy to symptomatic bone metastases allowed

• More than 2 weeks since minor surgery

• Insertion of a vascular access device allowed

• More than 3 weeks since prior dimethylxanthenone acetic acid for prophylactic cranial irradiation

• More than 4 weeks since major surgery (defined by the use of general anesthesia)

• At least 30 days since prior and no other concurrent investigational drugs or anti-cancer therapy

• No treatment in a clinical trial within 30 days prior to trial entry

• No concurrent therapy with a risk of causing Torsades de Pointes

• No concurrent drugs that would be contraindicated for use with study drugs

• No factors with the potential to prolong QT interval

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Lung Cancer
• Lung Neoplasms
• Small Cell Lung Carcinoma

Intervention

Drug:
• carboplatin
AUC 6 i.v. given after paclitaxel as the second treatment on day 1 of each 3-week cycle.
• paclitaxel
175 mg/m2 i.v. first treatment on day 1 of each 3-week cycle.
• vadimezan
1800 mg/m2 i.v. following the administration of paclitaxel and carboplatin on day 1 of each 3-week cycle

Locations

Country	Name	City	State
Switzerland	Saint Claraspital AG	Basel
Switzerland	Universitaetsspital-Basel	Basel
Switzerland	Istituto Oncologico della Svizzera Italiana - Ospedale San Giovanni	Bellinzona
Switzerland	Inselspital Bern	Bern
Switzerland	Spitalzentrum Biel	Biel
Switzerland	Centre Hospitalier Universitaire Vaudois	Lausanne
Switzerland	Kantonsspital Olten	Olten
Switzerland	Onkologie Schaffhausen	Schaffhausen
Switzerland	Kantonsspital - St. Gallen	St. Gallen
Switzerland	Regionalspital	Thun
Switzerland	Kantonsspital Winterthur	Winterthur
Switzerland	Klinik Hirslanden	Zurich

Sponsors (1)

Lead Sponsor	Collaborator
Swiss Group for Clinical Cancer Research

Country where clinical trial is conducted

Switzerland, 

References & Publications (1)

Früh M, Cathomas R, Siano M, Tscherry G, Zippelius A, Mamot C, Erdmann A, Krasniqi F, Rauch D, Simcock M, Küttel E, Fustier P, Pless M; Swiss Group for Clinical Cancer Research. Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensi — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free survival rate	The status of progression free survival at 24 weeks (+/- 2 weeks) from trial registration will be assessed. A PFS event is defined as (whichever occurs first): Relapse or progression assessed according to the RECIST 1.1 criteria (Appendix 1); Death of any cause.	at 24 weeks (6 months)	No
Secondary	Adverse events by NCI CTCAE v3.0		until 30 days after trial therapy end	Yes
Secondary	Best objective response OR complete or partial response according to RECIST 1.1		whilst receiving the trial therapy	No
Secondary	Time to progression		Defined as the time from registration until documented Small-cell Lung Cancer (SCLC) progression or death as a result of SCLC.	No
Secondary	Overall survival		Time from registration until death as a result of any cause.	No
Secondary	One-year survival rate	Patients alive one year after trial registration	at 1 year	No